Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion
Gang Chen, Chul-Kyu Park, Rou-Gang Xie, Ru-Rong Ji
Gang Chen, Chul-Kyu Park, Rou-Gang Xie, Ru-Rong Ji
View: Text | PDF
Research Article Neuroscience

Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion

  • Text
  • PDF
Abstract

Neuropathic pain remains a pressing clinical problem. Here, we demonstrate that a local, intrathecal (i.t.) injection of bone marrow stromal cells (BMSCs) following lumbar puncture alleviates early- and late-phase neuropathic pain symptoms, such as allodynia and hyperalgesia, for several weeks in murine chronic constriction injury (CCI) and spared nerve injury models. Moreover, i.t. BMSCs reduced CCI-induced spontaneous pain and axonal injury of dorsal root ganglion (DRG) neurons and inhibited CCI-evoked neuroinflammation in DRGs and spinal cord tissues. BMSCs secreted TGF-β1 into the cerebrospinal fluid, and neutralization of TGF-β1, but not IL-10, reversed the analgesic effect of BMSCs. Conversely, i.t. administration of TGF-β1 potently inhibited neuropathic pain. TGF-β1 acted as a powerful neuromodulator and rapidly (within minutes) suppressed CCI-evoked spinal synaptic plasticity and DRG neuronal hyperexcitability via TGF-β receptor 1–mediated noncanonical signaling. Finally, nerve injury upregulated CXCL12 in lumbar L4–L6 DRGs, and this upregulation caused migration of i.t.-injected BMSCs to DRGs through the CXCL12 receptor CXCR4, which was expressed on BMSCs. BMSCs that migrated from the injection site survived at the border of DRGs for more than 2 months. Our findings support a paracrine mechanism by which i.t. BMSCs target CXCL12-producing DRGs to elicit neuroprotection and sustained neuropathic pain relief via TGF-β1 secretion.

Authors

Gang Chen, Chul-Kyu Park, Rou-Gang Xie, Ru-Rong Ji

×

Figure 6

Exogenous TGF-β1 rapidly suppresses CCI-induced enhancement of excitatory synaptic transmission in lamina IIo neurons of spinal cord slices via the TGF-β1R.

Options: View larger image (or click on image) Download as PowerPoint
Exogenous TGF-β1 rapidly suppresses CCI-induced enhancement of excitator...
(A) Traces showing sEPSCs in lamina IIo neurons of spinal cord slices. (B) Frequency and amplitude of sEPSCs. CCI (day 4) induced profound increases in sEPSC frequency and amplitude, which were suppressed by TGF-β1 (2 or 10 ng/ml). Note that TGF-β1 had no effect on the frequency or amplitude of sEPSCs in sham control spinal cord. *P < 0.05, compared with sham surgery; #P < 0.05 compared with the control group; n = 5 neurons/group. (C) The TGF-β1R antagonist SB431542 blocked TGF-β1–induced inhibition of sEPSC frequency and amplitude. *P < 0.05; n = 5 neurons/group. Statistical significance was determined by 1-way ANOVA, followed by Bonferroni’s post-hoc test. All data are expressed as the mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts